AstraZeneca Rare Disease Drug Disappoints in Advanced Study

An experimental AstraZeneca Plc drug for a rare plasma cell disorder failed to delay death or reduce the number of hospitalizations for heart problems, dashing hopes that the medicine would help all patients with the most severe form of the condition.

The UK drugmaker said Wednesday that the drug, called anselamimab, did help a group of patients in the study and that it was still evaluating the trial results.